{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:19:28Z","timestamp":1762507168600},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T00:00:00Z","timestamp":1505260800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Deltanoid Pharmaceuticals, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s40268-017-0210-z","type":"journal-article","created":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T02:50:01Z","timestamp":1505271001000},"page":"597-605","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1\u03b1,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis"],"prefix":"10.1007","volume":"17","author":[{"given":"Richa","family":"Pandey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia B.","family":"Zella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinge G.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori A.","family":"Plum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Clagett-Dame","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Blaser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Bedale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hector F.","family":"DeLuca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel W.","family":"Coyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,13]]},"reference":[{"issue":"1","key":"210_CR1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","volume":"71","author":"A Levin","year":"2007","unstructured":"Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31\u20138.","journal-title":"Kidney Int."},{"key":"210_CR2","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1038\/ki.2010.191","volume":"117","author":"N Mittman","year":"2010","unstructured":"Mittman N, Desiraju B, Meyer KB, Chattopadhyay J, Avram MM. Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study. Kidney Int Suppl. 2010;117:S33\u20136.","journal-title":"Kidney Int Suppl."},{"issue":"3","key":"210_CR3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/nep.12029","volume":"18","author":"LM Ong","year":"2013","unstructured":"Ong LM, Narayanan P, Goh HK, Manocha AB, Ghazali A, Omar M, et al. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism. Nephrology (Carlton). 2013;18(3):194\u2013200.","journal-title":"Nephrology (Carlton)."},{"issue":"6","key":"210_CR4","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/ki.1994.223","volume":"45","author":"LD Quarles","year":"1994","unstructured":"Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomay D, et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int. 1994;45(6):1710\u201321.","journal-title":"Kidney Int."},{"issue":"5","key":"210_CR5","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.semnephrol.2004.06.013","volume":"24","author":"KJ Martin","year":"2004","unstructured":"Martin KJ, Gonzalez EA. Vitamin D analogs: actions and role in the treatment of secondary hyperparathyroidism. Semin Nephrol. 2004;24(5):456\u20139.","journal-title":"Semin Nephrol."},{"issue":"2","key":"210_CR6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ncpendmet0394","volume":"3","author":"AJ Brown","year":"2007","unstructured":"Brown AJ, Slatopolsky E. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Nat Clin Pract Endocrinol Metab. 2007;3(2):134\u201344.","journal-title":"Nat Clin Pract Endocrinol Metab."},{"issue":"4","key":"210_CR7","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","volume":"63","author":"SM Sprague","year":"2003","unstructured":"Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003;63(4):1483\u201390.","journal-title":"Kidney Int."},{"issue":"3","key":"210_CR8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/0886022X.2011.647298","volume":"34","author":"HZ Tonbul","year":"2012","unstructured":"Tonbul HZ, Solak Y, Atalay H, Turkmen K, Altintepe L. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study. Ren Fail. 2012;34(3):297\u2013303.","journal-title":"Ren Fail."},{"issue":"5","key":"210_CR9","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1517\/14740338.2013.791675","volume":"12","author":"CA Dyer","year":"2013","unstructured":"Dyer CA. Safety and tolerability of paricalcitol in patients with chronic kidney disease. Expert Opin Drug Saf. 2013;12(5):717\u201328.","journal-title":"Expert Opin Drug Saf."},{"issue":"23","key":"210_CR10","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.1021\/jm9802618","volume":"41","author":"RR Sicinski","year":"1998","unstructured":"Sicinski RR, Prahl JM, Smith CM, DeLuca HF. New 1\u03b1,25-dihydroxy-19-norvitamin D3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogues. J Med Chem. 1998;41(23):4662\u201374.","journal-title":"J Med Chem."},{"issue":"6","key":"210_CR11","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1159\/000362846","volume":"39","author":"JB Zella","year":"2014","unstructured":"Zella JB, Plum LA, Plowchalk DR, Potochoiba M, Clagett-Dame M, DeLuca HF. Novel, selective vitamin D analog suppresses parathyroid hormone in uremic animals and postmenopausal women. Am J Nephrol. 2014;39(6):476\u201383.","journal-title":"Am J Nephrol."},{"issue":"21","key":"210_CR12","doi-asserted-by":"crossref","first-page":"13487","DOI":"10.1073\/pnas.202471299","volume":"99","author":"NK Shevde","year":"2002","unstructured":"Shevde NK, Plum LA, Clagett-Dame M, Yamamoto H, Pike JW, DeLuca HF. A potent analog of 1\u03b1,25-dihydroxyvitamin D3 selectively induces bone formation. Proc Natl Acad Sci USA. 2002;99(21):13487\u201391.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"2","key":"210_CR13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.abb.2006.11.029","volume":"460","author":"JL Vanhooke","year":"2007","unstructured":"Vanhooke JL, Tadi BP, Benning MM, Plum LA, DeLuca HF. New analogs of 2-methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 with conformationally restricted side chains: evaluation of biological activity and structural determination of VDR-bound conformations. Arch Biochem Biophys. 2007;460(2):161\u20135.","journal-title":"Arch Biochem Biophys."},{"issue":"3","key":"210_CR14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000445756","volume":"43","author":"R Pandey","year":"2016","unstructured":"Pandey R, Zella J, Clagett-Dame M, Plum LA, DeLuca HF, Coyne DW. Use of 2MD, a novel oral calcitriol analog, in hemodialysis patients with secondary hyperparathyroidism. Am J Nephrol. 2016;43(3):213\u201320.","journal-title":"Am J Nephrol."},{"issue":"1","key":"210_CR15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000452680","volume":"45","author":"R Thadhani","year":"2017","unstructured":"Thadhani R, Zella JB, Knutson DC, Blaser WJ, Plum LA, Clagett-Dame M, et al. 2MD (DP001), a single agent in the management of hemodialysis patients: a randomized trial. Am J Nephrol. 2017;45(1):40\u20138.","journal-title":"Am J Nephrol"},{"issue":"1","key":"210_CR16","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1006\/abio.1997.2439","volume":"255","author":"NC Arbour","year":"1998","unstructured":"Arbour NC, Ross TK, Zierold C, Prahl JM, DeLuca HF. A highly sensitive method for large-scale measurements of 1,25-dihydroxyvitamin D. Anal Biochem. 1998;255(1):148\u201354.","journal-title":"Anal Biochem."},{"key":"210_CR17","unstructured":"Abbott-Laboratories. Zemplar (paricalcitol) capsules [package insert]. North Chicago; 2009."},{"issue":"Supplement","key":"210_CR18","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1046\/j.1523-1755.63.s85.20.x","volume":"85","author":"E Slatopolsky","year":"2003","unstructured":"Slatopolsky E, Finch J, Brown A. New vitamin D analogs. Kidney Int. 2003;85(Supplement):S83\u20137.","journal-title":"Kidney Int."},{"issue":"5","key":"210_CR19","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0272-6386(95)90455-7","volume":"26","author":"E Slatopolsky","year":"1995","unstructured":"Slatopolsky E, Finch J, Ritter C, Denda M, Morrissey J, Brown A, et al. A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis. 1995;26(5):852\u201360.","journal-title":"Am J Kidney Dis."},{"issue":"5","key":"210_CR20","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/ndt\/17.5.829","volume":"17","author":"L Brandi","year":"2002","unstructured":"Brandi L, Egfjord M, Olgaard K. Pharmacokinetics of 1,25(OH)(2)D-3 and 1 alpha(OH)D-3 in normal and uraemic men. Nephrol Dial Transplant. 2002;17(5):829\u201342.","journal-title":"Nephrol Dial Transplant."},{"issue":"34","key":"210_CR21","doi-asserted-by":"crossref","first-page":"31756","DOI":"10.1074\/jbc.M304737200","volume":"278","author":"H Yamamoto","year":"2003","unstructured":"Yamamoto H, Shevde NK, Warrier A, Plum LA, DeLuca HF, Pike JW. 2-Methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 potently stimulates gene-specific DNA binding of the vitamin D receptor in osteoblasts. J Biol Chem. 2003;278(34):31756\u201365.","journal-title":"J Biol Chem."},{"issue":"8","key":"210_CR22","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/sj.ki.5002451","volume":"72","author":"M Wolf","year":"2007","unstructured":"Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72(8):1004\u201313.","journal-title":"Kidney Int."},{"issue":"4","key":"210_CR23","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1681\/ASN.2004070573","volume":"16","author":"M Teng","year":"2005","unstructured":"Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005;16(4):1115\u201325.","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"210_CR24","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","volume":"349","author":"M Teng","year":"2003","unstructured":"Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349(5):446\u201356.","journal-title":"N Engl J Med."}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-017-0210-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-017-0210-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-017-0210-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,18]],"date-time":"2017-11-18T05:35:13Z","timestamp":1510983313000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-017-0210-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,13]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["210"],"URL":"https:\/\/doi.org\/10.1007\/s40268-017-0210-z","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,13]]}}}